OVARIAN UNDIFFERENTIATED CARCINOMA
Clinical trials for OVARIAN UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Measles virus hijacks stem cells to attack ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has returned after standard treatment. Doctors take stem cells from the patient's own fat tissue, infect them with a specially modified measles virus, and inject them into the abdomen. The idea is that the stem c…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 23, 2026 19:35 UTC
-
Experimental drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in women with ovarian cancer that has returned after platinum treatment. The study enrolls 54 participants and focuses on finding the safest dose and monitoring side effects. If …
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New drug combo may outperform chemo for returning ovarian cancer
Disease control OngoingThis study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New drug cocktail shows promise for resistant ovarian cancer
Disease control OngoingThis study tests whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemo. About 582 women took part.…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC
-
Weekly vs. standard chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal was…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC